Literature DB >> 1683314

Endometrial lesions in patients undergoing tamoxifen therapy.

X De Muylder1, P Neven, M De Somer, Y Van Belle, G Vanderick, E De Muylder.   

Abstract

Forty-six nonhysterectomized women treated with tamoxifen during 6-36 months as adjuvant therapy for breast cancer underwent a hysteroscopy to assess the endometrial effects of this drug. Whereas the endometrium was normal among 23 patients, 13 presented with endometrial polyps, 8 with hyperplasia and 2 with adenocarcinoma. The rate of endometrial lesions was directly related to the cumulative dose of tamoxifen but it was not statistically different among patients receiving progestational therapy compared to patients who did not receive this therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1683314     DOI: 10.1016/0020-7292(91)90767-y

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  18 in total

1.  Suppression of Estrogenic Activity by Medroxyprogesterone Acetate in Tamoxifen-treated Patients after Surgery for Breast Cancer to Reduce the Risk of Endometrial Cancer Development.

Authors: 
Journal:  Breast Cancer       Date:  1996-03-29       Impact factor: 4.239

2.  Benign endometrial adenofibroma and polyp in patients receiving tamoxifen: findings on transvaginal ultrasonography and magnetic resonance imaging.

Authors:  Akiko Ikuta; Yoshiaki Tanaka; Tomomi Mizokami; Akihiro Tsutsumi; Masahiro Sato; Maki Tanaka; Hideharu Kanzaki
Journal:  J Med Ultrason (2001)       Date:  2005-06       Impact factor: 1.314

3.  Metachronous Cancer of Breast and Adenocarcinoma of Cervix: A Rare Case Report.

Authors:  Nalini Sharma; J Lalnunnem Thiek; Das Rituparna; Jaya Mishra; Ahanthem Santa Singh
Journal:  J Menopausal Med       Date:  2017-08-31

4. 

Authors:  J C Rageth; L Bronz; S Granberg
Journal:  Arch Gynecol Obstet       Date:  1995-12       Impact factor: 2.344

5.  Tamoxifen and the uterus.

Authors:  P Neven; X De Muylder; Y Van Belle; R Campo; G Vanderick
Journal:  BMJ       Date:  1994-11-19

Review 6.  Tamoxifen and secondary tumours. An update.

Authors:  N Wilking; E Isaksson; E von Schoultz
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

7.  Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients.

Authors:  I Cohen; E Perel; D Flex; R Tepper; M M Altaras; M Cordoba; Y Beyth
Journal:  J Clin Pathol       Date:  1999-04       Impact factor: 3.411

8.  The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium.

Authors:  M J E Mourits; K A Ten Hoor; A G J van der Zee; P H B Willemse; E G E de Vries; H Hollema
Journal:  J Clin Pathol       Date:  2002-07       Impact factor: 3.411

Review 9.  Gynaecologic effects of tamoxifen.

Authors:  D Y Kuo; C D Runowicz
Journal:  Med Oncol       Date:  1995-06       Impact factor: 3.064

Review 10.  What do we know and what don't we know about tamoxifen in the human uterus.

Authors:  A Friedl; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.